|
|
 Previous Article | Table of Contents | Next Article 
Activated cytotoxic T cells as prognostic marker in Hodgkin's disease
JJ Oudejans, NM Jiwa, JA Kummer, GJ Ossenkoppele, P van Heerde, JW Baars, PM Kluin, JC Kluin-Nelemans, PJ van Diest, JM Middeldorp and CJ Meijer
Department of Pathology, Free University Hospital, Amsterdam, The
Netherlands.
Although the results of treatment of Hodgkin's disease (HD) have improved
considerably in the last decades, the disease remains fatal in a minority
of patients. We have recently shown that numbers of activated cytotoxic T
cells (CTLs), present in tumor biopsy specimens, differ considerably among
individual HD patients. Because CTLs are the major effector cells in
elimination of neoplastic cells, we investigated whether the number of
activated CTLs is related to the clinical outcome of the individual patient
with HD. Activated CTLs present in tumor biopsy specimens of patients with
nodular sclerosis or mixed cellularity HD were identified by
immunohistochemistry using an antibody directed against granzyme B (GrB), a
major constituent of the cytotoxic granules of activated CTLs and natural
killer cells, and an antibody directed against CD8. The presence of a high
percentage of GrB+ lymphocytes was found to be an unfavorable prognostic
marker. The large majority of GrB+ cells were also CD8+, indicating that
these cells are activated CTLs. Prognosis was found to decrease with
increasing percentages of GrB+ lymphocytes. Optimal discrimination between
patients with good and poor prognosis was obtained when the threshold was
set at 15% GrB+ cells; 6 of 10 patients with > or = 15% GrB+ lymphocytes
died as a result of the disease, as compared with 6 of 70 patients with
less than 15% GrB+ lymphocytes (P < .0001). In stage-2 patients, the
percentage of GrB+ lymphocytes retained its predictive value in a
multivariate analysis including histology, sex, age, erythrocyte
sedimentation rate, and the presence of B symptoms as covariables. In
addition, patients with > or = 15% GrB+ lymphocytes had a shortened
progression-free survival time (P = .002). We conclude that a high
percentage of activated CTLs present in biopsy material of HD patients is a
strong indicator for an unfavorable clinical outcome.
Volume 89,
Issue 4,
pp. 1376-1382,
02/15/1997
Copyright © 1997 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Diepstra, G. W. van Imhoff, M. Schaapveld, H. Karim-Kos, A. van den Berg, E. Vellenga, and S. Poppema
Latent Epstein-Barr Virus Infection of Tumor Cells in Classical Hodgkin's Lymphoma Predicts Adverse Outcome in Older Adult Patients
J. Clin. Oncol.,
August 10, 2009;
27(23):
3815 - 3821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Asano, K. Yamamoto, J.-I. Tamaru, T. Oyama, F. Ishida, K. Ohshima, T. Yoshino, N. Nakamura, S. Mori, O. Yoshie, et al.
Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients
Blood,
March 19, 2009;
113(12):
2629 - 2636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Sanchez-Espiridion, A. Sanchez-Aguilera, C. Montalban, C. Martin, R. Martinez, J. Gonzalez-Carrero, C. Poderos, C. Bellas, M. F. Fresno, C. Morante, et al.
A TaqMan Low-Density Array to Predict Outcome in Advanced Hodgkin's Lymphoma Using Paraffin-Embedded Samples
Clin. Cancer Res.,
February 15, 2009;
15(4):
1367 - 1375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Alvaro, M. Lejeune, J. F. Garcia, Ma. T. Salvado, C. Lopez, R. Bosch, J. Jaen, P. Escriva, and L. E. Pons
Tumor-Infiltrated Immune Response Correlates with Alterations in the Apoptotic and Cell Cycle Pathways in Hodgkin and Reed-Sternberg Cells
Clin. Cancer Res.,
February 1, 2008;
14(3):
685 - 691.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Diepstra, G. W. van Imhoff, H. E. Karim-Kos, A. van den Berg, G. J. te Meerman, M. Niens, I. M. Nolte, E. Bastiaannet, M. Schaapveld, E. Vellenga, et al.
HLA Class II Expression by Hodgkin Reed-Sternberg Cells Is an Independent Prognostic Factor in Classical Hodgkin's Lymphoma
J. Clin. Oncol.,
July 20, 2007;
25(21):
3101 - 3108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Grabenbauer, G. Lahmer, L. Distel, and G. Niedobitek
Tumor-Infiltrating Cytotoxic T Cells but not Regulatory T Cells Predict Outcome in Anal Squamous Cell Carcinoma.
Clin. Cancer Res.,
June 1, 2006;
12(11):
3355 - 3360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. van Houdt, J. J. Oudejans, A. J.M. van den Eertwegh, A. Baars, W. Vos, B. A. Bladergroen, D. Rimoldi, J. J.F. Muris, E. Hooijberg, C. M. Gundy, et al.
Expression of the Apoptosis Inhibitor Protease Inhibitor 9 Predicts Clinical Outcome in Vaccinated Patients with Stage III and IV Melanoma
Clin. Cancer Res.,
September 1, 2005;
11(17):
6400 - 6407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. F. Muris, S. A. G. M. Cillessen, W. Vos, I. S. van Houdt, J. A. Kummer, J. H. J. M. van Krieken, N. M. Jiwa, P. M. Jansen, H. C. Kluin-Nelemans, G. J. Ossenkoppele, et al.
Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas
Blood,
April 1, 2005;
105(7):
2916 - 2923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Alvaro, M. Lejeune, M. T. Salvado, R. Bosch, J. F. Garcia, J. Jaen, A. H. Banham, G. Roncador, C. Montalban, and M. A. Piris
Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells
Clin. Cancer Res.,
February 15, 2005;
11(4):
1467 - 1473.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Arens, M. A. Nolte, K. Tesselaar, B. Heemskerk, K. A. Reedquist, R. A. W. van Lier, and M. H. J. van Oers
Signaling through CD70 Regulates B Cell Activation and IgG Production
J. Immunol.,
September 15, 2004;
173(6):
3901 - 3908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kondratiev, E. Sabo, E. Yakirevich, O. Lavie, and M. B. Resnick
Intratumoral CD8+ T Lymphocytes as a Prognostic Factor of Survival in Endometrial Carcinoma
Clin. Cancer Res.,
July 1, 2004;
10(13):
4450 - 4456.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Montalban, J. F. Garcia, V. Abraira, L. Gonzalez-Camacho, M. M. Morente, J. L. Bello, E. Conde, M. A. Cruz, R. Garcia-Sanz, J. Garcia-Larana, et al.
Influence of Biologic Markers on the Outcome of Hodgkin's Lymphoma: A Study by the Spanish Hodgkin's Lymphoma Study Group
J. Clin. Oncol.,
May 1, 2004;
22(9):
1664 - 1673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Flanagan, J. Middeldorp, and T. Sculley
Localization of the Epstein-Barr virus protein LMP 1 to exosomes
J. Gen. Virol.,
July 1, 2003;
84(7):
1871 - 1879.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. Dukers, C. J. L. M. Meijer, R. L. ten Berge, W. Vos, G. J. Ossenkoppele, and J. J. Oudejans
High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome
Blood,
June 17, 2002;
100(1):
36 - 42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. F. Skinnider and T. W. Mak
The role of cytokines in classical Hodgkin lymphoma
Blood,
May 29, 2002;
99(12):
4283 - 4297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Bladergroen, C. J. L. M. Meijer, R. L. ten Berge, C. E. Hack, J. J. F. Muris, D. F. Dukers, A. Chott, Y. Kazama, J. J. Oudejans, O. van Berkum, et al.
Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?
Blood,
January 1, 2002;
99(1):
232 - 237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Vermeer, R. van Doorn, D. Dukers, M. W. Bekkenk, C. J.L.M. Meijer, and R. Willemze
CD8+ T Cells in Cutaneous T-Cell Lymphoma: Expression of Cytotoxic Proteins, Fas Ligand, and Killing Inhibitory Receptors and Their Relationship With Clinical Behavior
J. Clin. Oncol.,
December 1, 2001;
19(23):
4322 - 4329.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
O. Nakano, M. Sato, Y. Naito, K. Suzuki, S. Orikasa, M. Aizawa, Y. Suzuki, I. Shintaku, H. Nagura, and H. Ohtani
Proliferative Activity of Intratumoral CD8+ T-Lymphocytes As a Prognostic Factor in Human Renal Cell Carcinoma: Clinicopathologic Demonstration of Antitumor Immunity
Cancer Res.,
July 1, 2001;
61(13):
5132 - 5136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R L Ten Berge, J J Oudejans, D F Dukers, and C J L M Meijer
Anaplastic large cell lymphoma: what's in a name?
J. Clin. Pathol.,
June 1, 2001;
54(6):
494 - 495.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Schumacher, W. Haensch, C. Röefzaad, and P. M. Schlag
Prognostic Significance of Activated CD8+ T Cell Infiltrations within Esophageal Carcinomas
Cancer Res.,
May 1, 2001;
61(10):
3932 - 3936.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. F. Dukers, P. Meij, M. B. H. J. Vervoort, W. Vos, R. J. Scheper, C. J. L. M. Meijer, E. Bloemena, and J. M. Middeldorp
Direct Immunosuppressive Effects of EBV-Encoded Latent Membrane Protein 1
J. Immunol.,
July 15, 2000;
165(2):
663 - 670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Willenbrock, A. Roers, B. Blohbaum, K. Rajewsky, and M.-L. Hansmann
CD8+ T Cells in Hodgkin's Disease Tumor Tissue Are a Polyclonal Population with Limited Clonal Expansion but Little Evidence of Selection by Antigen
Am. J. Pathol.,
July 1, 2000;
157(1):
171 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Greer and W. Macon
Am. J. Pathol.,
July 1, 1999;
155(1):
325 - 326.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. ten Berge, D. F. Dukers, J. J. Oudejans, K. Pulford, G. J. Ossenkoppele, D. de Jong, J. F.M.M. Misere, and C. J.L.M. Meijer
Adverse Effects of Activated Cytotoxic T Lymphocytes on the Clinical Outcome of Nodal Anaplastic Large Cell Lymphoma
Blood,
April 15, 1999;
93(8):
2688 - 2696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Brice
Prognostic Factors in Advanced Hodgkin's Disease -- Can They Guide Therapeutic Decisions?
N. Engl. J. Med.,
November 19, 1998;
339(21):
1547 - 1549.
[Full Text]
|
|
|
|
|
|
|
K. Asadullah, M. Friedrich, W. Sterry, W.-D. Docke, and H.-D. Volk
Granzyme A mRNA Expression in Mycosis Fungoides Progression
Blood,
November 1, 1997;
90(9):
3810 - 3810.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Younes;, J. J. Oudejans, P. J. van Diest, P. M. Kluin, and C. J.L.M. Meijer
Are Activated Cytoxic T Cells in Hodgkin's Disease Biopsies a Poor Prognostic Marker?
Blood,
July 15, 1997;
90(2):
890 - 890.
[Full Text]
[PDF]
|
|
|
|
|
